D.E. Shaw & Co’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.67M Sell
389,499
-80,098
-17% -$879K ﹤0.01% 2408
2025
Q4
$5.83M Sell
469,597
-155,554
-25% -$2.07M ﹤0.01% 2186
2025
Q3
$8.96M Sell
625,151
-43,153
-6% -$591K 0.01% 1773
2025
Q2
$8.2M Buy
668,304
+326,674
+96% +$4.74M 0.01% 1648
2025
Q1
$7.51M Sell
341,630
-391,921
-53% -$9.22M 0.01% 1603
2024
Q4
$16.6M Sell
733,551
-289,713
-28% -$6.32M 0.01% 1148
2024
Q3
$18.6M Buy
1,023,264
+167,912
+20% +$3.89M 0.02% 1032
2024
Q2
$24.9M Buy
855,352
+335,557
+65% +$9.95M 0.02% 778
2024
Q1
$18.4M Buy
519,795
+107,938
+26% +$4.32M 0.02% 964
2023
Q4
$17.9M Sell
411,857
-35,733
-8% -$1.41M 0.02% 999
2023
Q3
$17.1M Buy
447,590
+43,922
+11% +$1.85M 0.02% 947
2023
Q2
$16.6M Buy
403,668
+54,618
+16% +$2.63M 0.02% 980
2023
Q1
$20M Sell
349,050
-14,743
-4% -$831K 0.02% 896
2022
Q4
$20.4M Buy
363,793
+56,439
+18% +$2.87M 0.02% 904
2022
Q3
$13M Buy
307,354
+3,048
+1% +$156K 0.02% 1148
2022
Q2
$16.4M Buy
304,306
+42,826
+16% +$2.57M 0.02% 1004
2022
Q1
$16.8M Buy
261,480
+227,936
+680% +$15M 0.02% 1156
2021
Q4
$2.25M Sell
33,544
-12,500
-27% -$846K ﹤0.01% 3252
2021
Q3
$3.15M Sell
46,044
-44,190
-49% -$3.12M ﹤0.01% 2578
2021
Q2
$6.16M Sell
90,234
-47,145
-34% -$3.33M 0.01% 1874
2021
Q1
$9.49M Sell
137,379
-65,764
-32% -$4.46M 0.01% 1391
2020
Q4
$13.2M Sell
203,143
-129,294
-39% -$6.96M 0.01% 1209
2020
Q3
$15.7M Sell
332,437
-52,430
-14% -$2.49M 0.02% 964
2020
Q2
$18.1M Sell
384,867
-110,264
-22% -$5.42M 0.02% 835
2020
Q1
$22.1M Buy
495,131
+92,553
+23% +$4.86M 0.03% 574
2019
Q4
$23.5M Sell
402,578
-21,114
-5% -$1.26M 0.03% 735
2019
Q3
$25.5M Sell
423,692
-6,900
-2% -$411K 0.03% 660
2019
Q2
$24M Sell
430,592
-52,694
-11% -$2.71M 0.03% 661
2019
Q1
$26.9M Buy
483,286
+47,297
+11% +$2.41M 0.03% 592
2018
Q4
$19.7M Sell
435,989
-17,040
-4% -$935K 0.03% 722
2018
Q3
$29.8M Sell
453,029
-59,730
-12% -$3.71M 0.04% 594
2018
Q2
$33M Buy
512,759
+373,809
+269% +$23.1M 0.04% 502
2018
Q1
$7.69M Buy
138,950
+3,899
+3% +$204K 0.01% 1149
2017
Q4
$6.46M Sell
135,051
-8,081
-6% -$396K 0.01% 1317
2017
Q3
$7.22M Sell
143,132
-119,690
-46% -$6.15M 0.01% 1130
2017
Q2
$14.3M Sell
262,822
-30,393
-10% -$1.45M 0.02% 732
2017
Q1
$12.4M Buy
293,215
+226,997
+343% +$9.7M 0.02% 794
2016
Q4
$2.84M Buy
66,218
+43,710
+194% +$1.78M ﹤0.01% 1747
2016
Q3
$929K Sell
22,508
-55,608
-71% -$2.33M ﹤0.01% 2426
2016
Q2
$3.12M Sell
78,116
-71,182
-48% -$2.56M 0.01% 1608
2016
Q1
$5.03M Sell
149,298
-22,288
-13% -$694K 0.01% 1273
2015
Q4
$5.82M Buy
171,586
+1,738
+1% +$54.3K 0.01% 1302
2015
Q3
$5.06M Buy
169,848
+67,747
+66% +$2.12M 0.01% 1384
2015
Q2
$2.81M Buy
102,101
+66,121
+184% +$1.76M ﹤0.01% 1924
2015
Q1
$907K Buy
35,980
+5,225
+17% +$124K ﹤0.01% 2642
2014
Q4
$682K Sell
30,755
-256
-0.8% -$5.19K ﹤0.01% 3109
2014
Q3
$629K Buy
+31,011
New +$617K ﹤0.01% 3167
2014
Q2
Sell
-37,558
Closed -$706K 4343
2014
Q1
$706K Sell
37,558
-73,304
-66% -$1.41M ﹤0.01% 3326
2013
Q4
$2.16M Buy
+110,862
New +$2.03M ﹤0.01% 2459

Other funds holding IART

D.E. Shaw & Co's IART Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Integra LifeSciences (IART) stake by 17% in Q1 2026, selling an estimated $879K and leaving 389,499 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2408.

D.E. Shaw & Co first reported a position in IART in Q4 2013 and has held it in 49 quarters since. The position peaked at $33M in Q2 2018. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • D.E. Shaw & Co held 389,499 shares of Integra LifeSciences worth $3.67M as of Q1 2026.
  • D.E. Shaw & Co sold 80,098 Integra LifeSciences shares in Q1 2026, an estimated $879K.
  • Integra LifeSciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2408 holding.
  • D.E. Shaw & Co first reported a position in Integra LifeSciences in Q4 2013 and has held it in 49 quarters since.
  • D.E. Shaw & Co's Integra LifeSciences position peaked at $33M in Q2 2018.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.